Phase II Study of RO4929097 to Eradicate Residual Disease in Patients With Multiple Myeloma Post Single Autologous Stem Cell Transplant.
Phase of Trial: Phase II
Latest Information Update: 04 Mar 2017
At a glance
- Drugs RG 4733 (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Therapeutic Use
- 19 Jul 2016 Status changed from withdrawn prior to enrolment to discontinued.
- 24 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.